We are live on ! Find out more
TCRT icon

Alaunos Therapeutics

122 hedge funds and large institutions have $356M invested in Alaunos Therapeutics in 2017 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 34 increasing their positions, 31 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 31

9% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 11

0% more funds holding

Funds holding: 122122 (0)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0.01% less ownership

Funds ownership: 0.28%0.27% (-0.01%)

5% less capital invested

Capital invested by funds: $376M → $356M (-$19.8M)

47% less call options, than puts

Call options by funds: $4.96M | Put options by funds: $9.29M

Holders
122
Holders Change
Holders Change %
0%
% of All Funds
3.04%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
12
Increased
34
Reduced
31
Closed
11
Calls
$4.96M
Puts
$9.29M
Net Calls
-$4.33M
Net Calls Change
-$255K
Name Holding Trade Value Shares
Change
Change in
Stake
Squarepoint
126
Squarepoint
New York
-$359K -385 Closed
SI
127
Stephens Inc
Arkansas
-$243K -261 Closed
GLRA
128
Gerald L. Ray & Associates
Texas
-$136K -146 Closed
ProShare Advisors
129
ProShare Advisors
Maryland
-$72K -77 Closed
MLM
130
Mount Lucas Management
Pennsylvania
-$40K -43 Closed
CPA
131
Cowen Prime Advisors
New York
-$20K -21 Closed
MLFP
132
MPS Loria Financial Planners
Illinois
-$10K -12 Closed
PSUF
133
People's United Financial
Connecticut
-$4K -4 Closed

TCRT Hedge Fund Activity: Q3 2017 in Review

122 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q3 2017, worth a combined $356M — down 5.3% from $376M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new TCRT positions and 11 closed out — a net gain of 1 holder — while 34 added to existing stakes and 31 trimmed.

The largest buyer was BlackRock, adding an estimated $2.71M. The largest seller was Susquehanna International Group, cutting an estimated $16.2M.

  • 122 institutional investors held Alaunos Therapeutics (TCRT) as of Q3 2017, unchanged from Q2 2017.
  • Funds reported $356M of Alaunos Therapeutics stock for Q3 2017, down 5.3% quarter-over-quarter.
  • 12 funds opened new Alaunos Therapeutics positions in Q3 2017 and 11 closed out, a net change of +1 holder.
  • The largest Alaunos Therapeutics buyer in Q3 2017 was BlackRock, an estimated $2.71M added.
  • The largest Alaunos Therapeutics seller in Q3 2017 was Susquehanna International Group, an estimated $16.2M sold.

Based on aggregated 13F filings for Q3 2017.